Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Defining asthma control
How do patient perceptions of asthma control differ from guideline definitions?
Relvar and cortisol levels
For inhaled corticosteroids, measuring cortisol suppression is the most sensitive and easily monitored biomarker of adverse systemic effects.1
The maximum ICS dose licensed with Relvar is substantially lower than that estimated for 20% cortisol suppression.*1 In fact, geometric mean 24-hour serum cortisol has been shown to be similar after 42 days of treatment with Relvar to that seen with placebo.2
Maximum licensed dose in ICS/LABA therapy and dose estimated to cause 20% cortisol suppression based on pharmacological modelling data1
This graph has been independently created by GSK from the original data. The same results were first published in Daley-Yates PT. Br J Clin Pharmacol 2015;80:372–380.
Fluticasone furoate is not licensed for use as monotherapy.
24-hour serum cortisol at Day 42 of treatment
This graph has been independently created by GSK from the original data. The same results were first published in Allen A, et al. Clin Respir J 2013;7:397–406.
Discover Relvar
Need help with this product?
Footnotes
*Indirect data comparison based on PK/PD modelling. The model uses 20% cortisol suppression as the lowest boundary of detectable systemic exposure for corticosteroids, serving as a cut-off point above which the adverse events of corticosteroids become more likely.1
Abbreviations
DPI, dry powder inhaler; FF, fluticasone furoate; HFA, hydrofluoroalkane; HPA, hypothalamicpituitary-adrenal; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; OD, once daily; PD, pharmacodynamic; PK, pharmacokinetic.
References
- Daley-Yates PT. Br J Clin Pharmacol 2015;80:372–380.
- Allen A, et al. Clin Respir J 2013;7:397–406.
- Global Datasheet Fluticasone furoate/vilanterol: v11, March 2020.
- Symbicort 400/12 Turbohaler SmPC, 2020.
- Seretide 500 Accuhaler SmPC, 2020.
- Fostair 200/6 NEXThaler SmPC, 2019.
RELVAR Ellipta was created in collaboration with
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Relvar is a registered trademark of the GlaxoSmithKline group of companies
PM-IE-FFV-WCNT-230008 June 2023
